Studies showed elevated cell-free hemoglobin (Hb) in preeclampsia (PE), and Hb reacts with nitric oxide (NO), decreasing its bioavailability. Haptoglobin (Hp) is a polymorphic protein (Hp1-1, Hp2-1 and Hp2-2) that binds Hb to form a complex that is removed from circulation, thus preventing Hb-driven oxidative stress and NO scavenging. Hp protein products differ in biochemical and biophysical properties, which reflects on the Hb-Hp complex clearance rate. We hypothesized that Hp phenotypes modulate NO bioavailability by influencing NO consumption in PE. We studied 92 PE subjects and 105 normal pregnant women (NP). Hp genotypes were determined using real-time PCR. To assess NO bioavailability, we measured plasma nitrite using an ozone-based chemiluminescence assay. Plasma Hb and Hp were assessed with commercial immunoassays. A NO consumption assay was used to measure NO consumption. We found no differences in Hp genotype frequencies between PE and NP groups. Hp genotypes had no effects on plasma heme levels, NO consumption and plasma nitrite in NP. However, in PE, Hp2-1 and Hp2-2 were associated with higher plasma heme levels (48 and 55% higher, respectively; Po0.05), increased NO consumption (42 and 44% more, respectively; Po0.05) and lower plasma nitrite (39% less for Hp2-2; Po0.05) compared with Hp1-1. These findings indicate that although Hp genotype does not affect the risk of PE, Hp1-1 genotype may exert a protective role in PE by reducing NO scavenging, whereas Hp2-1 and Hp2-2 further may aggravate PE by reducing NO bioavailability.
INTRODUCTION
Nitric oxide (NO) has an important role in the hemodynamic changes found during healthy pregnancy. 1 Increased heart rate, plasma volume and cardiac output over the course of a normal pregnancy are accompanied by decreased total peripheral vascular resistance and arterial blood pressure. 2 However, preeclampsia (PE) is associated with impaired vasodilation of the maternal systemic circulation, 3 possibly due to decreased NO bioavailability resulting due to lower NO production 4 and increased NO degradation. 5 In fact, altered circulating levels of angiogenic factors, 6 increased arginase expression, 7 oxidative stress, 8 eNOS inhibition by high concentrations of asymmetric dimethylarginine 9 and genetic variations 10 have all been suggested to impair NO bioavailability in PE.
We have recently reported increased circulating cell-free hemoglobin (Hb) levels in PE, 5 and this alteration may contribute to impaired NO bioavailability, because cell-free Hb scavenges NO through a high speed dioxygenation reaction in which NO reacts with oxyhemoglobin to form methemoglobin and nitrate, 11 thus compromising the efficiency of the NO/soluble guanylyl cyclase pathway to elicit vasodilatory activity.
In other disease conditions associated with Hb decompartmentalization into plasma such as sickle-cell disease, NO consumption by cell-free plasma Hb has been shown to cause hypertension, increased systemic and pulmonary vascular resistance and endothelial dysfunction. 12 Moreover, free heme catalyzes the formation of reactive oxygen species , such as superoxide anion, which in turn reacts with NO further impairing NO bioavailability and producing a much more powerful oxidant, peroxynitrite, 13 which is an important oxidant leading to endothelial cell injury and vascular inflammatory disorders. 14 In order to avoid iron loss and oxidative damage mediated by cell-free heme after intravascular hemolysis, the serum protein haptoglobin (Hp) binds to Hb to form a complex Hb-Hp that is rapidly removed from the circulation by the macrophage CD163 receptor expressed on Kupffer cells in the liver. 15 The human Hp gene is polymorphic with two common alleles (Hp 1 and Hp 2 ) encoding 3 different proteins (Hp1-1, Hp2-1 and Hp2-2). The allele Hp 1 is composed of 5 exons and the allele Hp 2 of 7 exons. The allele Hp 2 , present only in humans, apparently resulted from duplicated exons 3 and 4 of the Hp 1 gene. 16 As the multimerization domain is located in the exon 3 of the Hp gene, the duplication generates a bivalent Hp2 protein, unlike Hp1, which is monovalent. Therefore, Hp protein is a dimer in Hp1-1, a linear polymer in Hp2-1 and a cyclic polymer in Hp2-2 individuals. 17 These differences in Hp structure appear to have clinical importance due to functional differences in protecting against Hb-driven oxidative stress and NO consumption. 11 Indeed, it has been reported that Hb-Hp complex holds Hb dimer in a ferrous oxidation state that scavenges and inactivates NO through dioxygenation reaction, inhibiting endotheliumdependent relaxation. 18, 19 This observation provides a possible mechanism to explain the associations of Hp phenotypes recently 1 described in PE 20 with increased cell-free Hb and decreased NO levels found in women with this syndrome. 5 Considering the effects of reduced NO bioavailability in PE, and that increased levels of cell-free Hb and Hb-Hp complexes rapidly scavenge NO, we hypothesized that different Hp phenotypes might differ in their protective effects against NO consumption by plasma of normal pregnant (np) and PE women. We tested this possibility in the present study.
MATERIALS AND METHODS Subjects
This study was approved by the Institutional Review Board at the Faculty of Medicine of Ribeirao Preto, University of Sao Paulo, Brazil. A total of 197 pregnant women were enrolled in the Department of Obstetrics and Gynecology, University Hospital of the Faculty of Medicine of Ribeirao Preto. Of these, 105 were healthy pregnant women with uncomplicated pregnancies and 92 had PE. Hypertensive disorders were defined in accordance with the guidelines of the NHBPEP (National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy). 21 Preeclampsia was defined as increased blood pressure (X140 mm Hg systolic or X90 mm Hg diastolic on two or more measurements at least 6 h apart) with significant proteinuria (X0.3 g/ 24 h) in a woman after 20 weeks of gestation. No women with HELLP (hemolysis, elevated liver enzymes and low platelet count) syndrome or preexisting hypertension, with or without superimposed PE, were included in the present study. Exclusion criteria included twin or multiple pregnancies or any evidence of previous medical illness. At the time of clinic consultation, maternal venous blood samples were collected into standard EDTA or into heparin Vacutainer tubes (Becton-Dickinson, Sao Paulo, Brazil) with a 21 gauge needle. The tubes were immediately centrifuged at 1000 g for 3 min at room temperature, and plasma samples were stored at À 70 1C until they were used to measure plasma nitrite, NO consumption, plasma Hb and Hb levels. 19, 22 To avoid sample contamination with nitrites, especial care was taken with regard to the reagents and tubes used in the experiments, which were prewashed with Milli-Q (Synthesis; Millipore, Billerica, MA, USA) water to make sure that we would have no nitrite contamination. Genomic DNA was extracted from the cellular component of 1 ml of whole blood and stored at À 20 1C to determine Hp genotypes.
Measurement of Hb and Hp concentrations
ELISA kits were used to measure plasma Hb (Cat.No.E88-135, Bethyl Laboratories Inc., Montgomery, TX, USA) and Hp (ab108856, Abcam Inc., Cambridge, MA, USA) concentrations, according to the manufacturers' instructions.
Measurement of plasma nitrite concentrations
Plasma aliquots were analyzed in triplicate for their nitrite content using an ozone-based chemiluminescence assay, as previously described. 22 In brief, 200 ml of plasma samples were injected into a solution of acidified tri-iodide, purging with nitrogen inline with a gas-phase chemiluminescence NO analyzer (Sievers Model 280 NO Analyzer, Boulder, CO, USA). Approximately 8 ml of tri-iodide solution (2.0 g of potassium iodide and 1.3 g of iodine dissolved in 40 ml of water and 140 ml of acetic acid) were placed in the purge vessel into which plasma samples were injected. The tri-iodide solution reduced nitrites to NO gas, which was detected by the NO analyzer. For data acquisition we used the Liquid Program (version 3.21, Sievers, Boulder, CO, USA) and for data analysis we integrated the tracings peak by peak to obtain the area under the curve (measured in mV) with ORIGIN Version 8.5 (OriginLab, Northampton, MA, USA).
NO Consumption Assay
In order to assess NO consumption by plasma samples, we used a previously described assay. 19 Briefly, a solution of 40 mM DETA-NONOate (Cayman Chemical, Ann Arbor, MI, USA) in PBS (pH 7.4) was prepared in a glass vessel purged with nitrogen inline with an NO chemiluminescence analyzer (Sievers Model 280 NO Analyzer, Boulder, CO, USA) to produce a steadystate NO signal of about 30-50 mV. This signal is generated by the decay of DETA-NONOate and the release of NO from DETA-NONOate, thus producing a stable baseline signal. Thereafter, we injected 50 ml of plasma samples in triplicate, which produced decreases in baseline NO signal (NO consumption, mV), which was acquired with the Liquid Program (version 3.21).
The data were transferred and analyzed with the software program ORIGIN Version 8.5 (OriginLab, Northampton, MA, USA) and the area under the curve of decreasing NO signal over time was measured for each plasma sample. The intraassay and interassay coefficients of variation were o6%.
To demonstrate that NO scavenging was sensitive to iron oxidation, we incubated plasma samples from PE women with potassium ferricyanide III (Sigma Aldrich, St Louis, MO, USA; 0.5 mM final concentration) for 45 min at room temperature before injecting the plasma into the NO analyzer.
Haptoglobin genotyping
Genotypes for the duplication of exons 3 and 4 of Hp gene (alleles Hp 1 and Hp 2 ) were determined by a previously described method using real-time PCR 23 with slight modifications. Briefly, a Taqman probe (Hp2; Sigma Aldrich; sequence in Table 1 ) was designed to anneal at the junction of the end of exon 4 and the beginning of the duplicated allele (sequence that does not exist in Hp 1 homozygotes, only in heterozygous Hp 1 /Hp 2 -1 copy, and in homozygous Hp 2 -2 copies). Another probe (Hp5 0 , Sigma Aldrich; sequence in Table 1 ) was designed to anneal at the promoter of Hp gene acting as an internal control. Copy number of the Hp2 sequence was assessed relatively to the amplification of the internal control using the 2 À DDCT method ( Table 2) . Real-time PCR reactions were performed with Taqman Core Reagents Kit (Applied Biosystems, Carlsbad, CA, USA) as multiplex assays at the following conditions: 1 Â reaction buffer, dNTPs at 200 mM, MgCl 2 at 3.5 mM, primers Hp5' forward and reverse at 60 nM, Hp2 forward and reverse at 105 nM, probe HP5 0 at 42 nM, probe Hp2 at 100 nM, 0.25 units of AmpliTaq Gold, 0.1 units of AmpErase and between 3-8 ng of template DNA in a total reaction volume of 10 ml. Standard cycling programs for Taqman probes were used and reactions were performed at a StepOne Plus Real Time PCR machine (Applied Biosystems). Samples in which genotypes were previously assessed by direct sequencing were used as positive controls for each genotype and all samples were genotyped at least twice to ensure data quality.
Statistical analysis
The clinical and biochemical characteristics of study groups were compared by unpaired Student t-test or w 2 -tests. The distribution of genotypes was assessed for deviation from the Hardy-Weinberg equilibrium and differences in genotype frequencies were assessed using w 2 -tests. Two-way (polymorphisms vs. disease) analysis of variance followed by Bonferroni's post-test and one-way analysis of variance followed by Dunn's multiple comparison post-test were used to compare polymorphisms and biochemical parameters between group. The Spearman's correlation (rs, P) was calculated for associations between plasma heme concentrations and NO consumption. The data are shown as mean ± s.e.m. and a probability Po0.05 was considered statistically significant. Statistical analysis was performed with Prism 5 Software (Graphpad Prism, San Diego, CA, USA).
RESULTS
Patients' characteristics are detailed in Table 3 . No significant differences were found in race, age, Hb and hematocrit. However, subjects in the PE group had higher systolic and diastolic blood pressure, proteinuria, higher body mass index, lower gestational age at delivery and lower birth weight when compared with NP women (Table 3 ; Po0.05).
When comparing NP and PE groups, we found that plasma from patients with PE had lower nitrite levels (Figure 1a ; Po0.05) associated with increased plasma cell-free Hb concentrations (Figure 1b ; Po0.05) and reduced Hp levels (Figure 1c ; Po0.05).
Interestingly, we found higher NO consumption by plasma samples from patients with PE compared with NP (Figure 2c ; Po0.05) and this variable correlated significantly with Hb concentrations, expressed as heme (Figure 2d ; rs ¼ 0.641; Po0.001). This is consistent with the dioxygenation reaction, where ferrous oxyhemoglobin reacts with NO to form nitrate and methemoglobin in a 1:1 stoichiometry reaction (1 mole of heme consumes 1 mole of NO). Known concentrations of Hb solutions were used to calculate a standard curve for NO consumption (Figure 2a) . To further illustrate NO scavenging by plasma samples in PE and NP, we show decreases in the baseline NO signal (NO signal, mV) after plasma samples injections (Figure 2b) . Therefore, as Hb scavenges NO and Hp binds Hb with high affinity to accelerate its clearance, 11 we evaluated if Hp polymorphisms (which are known to alter Hp half-life) are associated with variations in plasmatic NO levels, cell-free Hb, and NO consumption by plasma from PE and NP groups.
Although Hp genotype distribution (Table 4) did not show differences in frequency between PE patients and NP women, we found significantly lower plasma nitrite in samples from PE patients carrying the allele Hp 2 (Hp2-1 and Hp2-2), compared with NP women carrying the same allele (33 and 54% less, respectively; Figure 3a , Po0.05). Interestingly, Hp2-1 and Hp2-2 phenotypes in PE resulted in significantly higher plasma levels of heme (41 and 45% more, respectively; Figure 3b , Po0.05) and also higher NO consumption (40 and 33% more, respectively; Figure 3c , Po0.05) compared with NP women.
Moreover, among patients with PE, Hp2-2 genotype showed lower nitrite levels when compared with Hp1-1 (80.22±7.42 nM versus 131.60±13.73 nM, respectively; Figure 2a , Po0.05). Though not statistically significant, nitrite concentrations in Hp2-1 were also reduced in relation to Hp1-1 (Figure 2a ).
In parallel with the reduction in nitrite levels found among patients with PE, we found higher plasma levels of heme in Hp2-1 and Hp2-2 in comparison with Hp1-1, (5.60 ± 0.49 mM and 6.39 ± 0.63 mM versus 2.86 ± 0.35 mM respectively; Figure 3b , Po0.05) and increased NO consumption (4.96±0.44 mM and 5.14 ± 0.52 mM versus 2.87 ± 0.20 mM respectively; Figure 3c , Po0.05).
Finally, we found lower Hp concentrations associated with genotypes Hp2-1 and Hp2-2 in PE, comparing them to NP women (Figure 3d ; Po0.05) and to PE women with Hp1-1 genotype (Figure 3d ). The reduction in Hp levels is consistent with the increased plasma cell-free Hb concentration in PE.
DISCUSSION
This is the first study to show that Hp polymorphisms modulate NO bioavailability in women with PE. Interestingly, we found increased NO consumption in association with increased cell-free Hb in plasma from PE patients carrying the allele Hp 2 of the Hp gene. Moreover, we show for the first time that Hp1-1 phenotype may protect PE women against NO scavenging by cell-free Hb.
Recently, different groups have reported increased circulating cell-free Hb levels in patients with PE, as compared with those found in normal pregnancy (NP), 5, 24 thus suggesting that Hb decompartmentalization may be involved in the pathogenesis of PE. Additionally, Hb subunits alpha2 and gamma are overexpressed in the PE placenta leading to accumulation of Hb in the vascular lumen of the placenta and consequently to fetal and adult Hb leakage into the maternal circulation. 24, 25 Abbreviation: s.d., standard deviation. The copy number variation was assessed by relative quantification of the junction between exon 4 and the duplicated allele and the promoter of the gene by the well-established 2 À DDCT method. As the internal control always has two copies, the relative quantity of the homozygous HP 2 /HP 2 , which carries two copies of the HP2 sequence is around one. Therefore, as the heterozygous HP 1 /HP 2 will have only one copy of HP2 sequence for each two copies of the internal control, the relative quantity is around 0.5. Finally, we did not detect the amplification of the HP2 probe in HP 1 /HP 1 homozygous samples, therefore, the ratio with the two copies of the internal control is zero. The distribution of genotypes for the three polymorphisms studied here showed nodeviation from Hardy-Weinberg equilibrium.
Red blood cell lysis of maternal systemic or intervillous circulation, or from fetal red blood cells in a leaky placental barrier, scavenges NO in a fast and irreversible dioxygenation reaction that produces nitrate (NO 3 À ) and methemoglobin. 19 Under normal physiological conditions, this reaction rate is highly limited as NO reacts much more slowly with compartmentalized Hb than with cell-free Hb. This is explained by diffusional barriers to NO around the red blood cell and intravascular blood flow. Red blood cellss occupy a central position in flowing blood, and are separated from the endothelium by laminar plasma, and therefore are relatively far from where NO is synthesized. 26 However, Hb release during hemolysis blocks these mechanisms that protect NO from being scavenged by Hb.
Our present results expand previous findings 5, 12 and show that micromolar concentrations of plasma cell-free Hb are capable of scavenging NO from plasma (Figure 2d) , possibly contributing to the cardiovascular derangements commonly found in PE. Interestingly, we found lower nitrite levels in PE (Figure 1a) , and this finding may partly reflect increased NO consumption. In another clinical study performed in patients with sickle-cell anemia, it was reported that NO consumption by cell-free plasma Hb impaired the vascular function in subjects with heme concentrations as low as 6 mmol l À 1 .
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Kim-Shapiro et al. 27 have shown in a theoretical model for NO availability within blood vessels that, at low hematocrits, small concentrations of cell-free Hb have more important effects on NO bioavailability due to increased NO consumption. However this factor cannot be invocated in PE, which presents with increased hematocrit when compared with normal pregnancies due to decreased volume expansion. Owing to this, another NO scavenging factor that may participate in PE is the complex formed by Hb and Hp (Hb-Hp). This complex holds Hb dimer in a ferrous oxidation state, which consumes NO through a dioxygenation reaction, thus inhibiting endothelium-dependent relaxation. 18, 19 These observations may help to explain the differences in irondriven oxidative stress and antioxidant properties associated with the different Hp protein structures found in humans. 15 In our experiments, we found increased cell-free Hb associated with higher NO consumption and reduced Hp concentrations in Hp2-1 and Hp2-2 genotypes in PE compared with normal pregnancy (Figures 3b, c and d) . Interestingly, Hp1-1 in PE did not show significant increases in plasma heme or NO consumption compared with normal pregnancy. These findings are consistent with other studies in PE where Hp1-1 was considered a protective factor against Hb-driven oxidative stress, 20 whereas Hp2-2 was shown to be a risk factor for cardiovascular disease. 28 However, we found no significant differences in blood pressure or proteinuria when the different Hp genotype groups were compared, thus suggesting that PE subjects with Hp1-1 genotype did not have milder forms of PE.
In Hp1-1 subjects, the Hp protein is found as a dimer, and as it has a smaller size than the linear (Hp2-1) and the cyclic (Hp2-2) polymers found in other genotypes, it can bind to and clear more molecules of Hb via monocyte/macrophage scavenger receptor CD163, thus conferring protection against oxidative stress.
11
In our study, we show that PE patients with phenotypes Hp2-1 and Hp2-2 had increased concentrations of plasma heme associated with increased NO consumption when compared with Hp 1-1 (Figures 3b and c) . This is consistent with other findings where Hb-Hp1-1 complexes were demonstrated to be cleared more rapidly than Hb-Hp2-2 complexes. 28 As NO consumption via dioxygenation reaction occurs at the same rate for cell-free Hb and for Hb bound to either Hp1-1 or Hp2-2, it has been proposed that different uptake rates of the Hb-Hp1-1 and Hb-Hp2-2 complexes by macrophages could have a profound effect on NO bioavailability. 11 Furthermore, the CD163 macrophage/monocyte receptor, which binds Hb-Hp complexes, has been shown to be downregulated 29 and upregulated 30 in different clinical conditions. Thus, besides Hp phenotype, CD163 expression might also have a clinical importance in regulating the rate in which Hb-Hp complexes are scavenged in PE, but this possibility remains to be tested.
The present study has some limitations. Firstly, we have not proven that cell-free Hb directly contributes to hypertension in PE. However, there are many previous studies showing that hemolysis may contribute to hypertension and other clinical conditions. 26 Secondly, we have not shown differences in Hp genotype frequencies, which might be due to our small sample size. However, the two largest studies comparing Hp phenotypes frequencies in PE have shown that Hp1-1 have a higher prevalence in normal pregnancy 20 and that Hp2-1 is associated with higher PE risk in Caucasian women, 31 thus supporting our results. Moreover, Hp2-2 was shown to have a higher incidence in pregnancy-associated hypertension. 32 Further prospective studies to examine whether plasma Hb concentrations and NO consumption vary over the course of pregnancy and correlate with hemodynamic parameters in PE are necessary to refine our findings.
This study may have relevant clinical implications. It is possible that pharmacological therapies that restore NO-cGMP activity or protect against hemolysis-driven NO scavenging in PE may attenuate the hemodynamic changes associated with this syndrome. In fact, small-molecule therapies like inhaled NO and carbon monoxide, nitrite infusion and endothelin receptor antagonists have been shown to ameliorate clinical signs of patients with sickle-cell disease, which is an important hemolytic condition. 33 Furthermore, treatment with eNOS substrate L-arginine, 34 inhibition of phosphodiesterase type 5 with sildenafil 35 and enhancing heme oxygenase activity (which degrades heme) by administering statins 36 have been shown to ameliorate PE symptoms in animal models of PE through pathways that might increase NO bioavailability. However, these therapies remain to be tested in clinical trials.
In conclusion, our results may have clinical importance because they suggest a functional association between Hp polymorphisms, 
